NOTIFICATION

Addendum

The following communication, dated 14 September 2022, is being circulated at the request of the delegation of Brazil.

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Title:** Public Consultation No. 1044, 8 April 2021.

|  |  |
| --- | --- |
| **Reason for Addendum:** | |
| [ ] | Comment period changed - date: |
| [X] | Notified measure adopted - date: 3 October 2022 |
| [ ] | Notified measure published - date: |
| [ ] | Notified measure enters into force - date: |
| [ ] | Text of final measure available from[[1]](#footnote-1): |
| [ ] | Notified measure withdrawn or revoked - date:  Relevant symbol if measure re-notified: |
| [ ] | Content or scope of notified measure changed and text available from1:  New deadline for comments (if applicable): |
| [ ] | Interpretive guidance issued and text available from1: |
| [ ] | Other: |

**Description:** The Public Consultation No. 1044, 8 April 2021 - previously notified through G/TBT/N/BRA/1165 - which establishes the criteria for the exemption and substitution of relative bioavailability and bioequivalence studies, was adopted as Resolution - RDC number 749, 05 September 2022

The final text is available only in Portuguese and can be downloaded at:

<http://antigo.anvisa.gov.br/documents/10181/2695968/RDC_749_2022_.pdf/d8c6877a-b162-49e8-944b-e1e88f7ef6ef>

**\_\_\_\_\_\_\_\_\_\_**

1. This information can be provided by including a website address, a pdf attachment, or other information on where the text of the final/modified measure and/or interpretive guidance can be obtained. [↑](#footnote-ref-1)